Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Chief Technical Officer | January 02, 2026 | January 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date January 02, 2026 · Filed January 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,721 |
Reported balance
After 2026-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-02 · Sale · Disposed 2,401 · Balance 77,721 F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2: Includes 2,834 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 106,321 |
Reported balance
After 2026-01-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 28,600 · Balance 106,321 F3: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.65 · Expires 2036-01-01 | Direct | 100,100 |
Reported balance
After 2026-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-02 · Grant · Acquired 100,100 · Balance 100,100 F4: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: Includes 2,834 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2025.
F3: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
F4: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 100,100 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001960264-26-000002 · form4-01022026_090107.xml · derivative · entry 3 Winter Charles M. · CIK 0001960264 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,100 Underlying: Common Stock · 100,100 shares Expires 2036-01-01 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 28,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001960264-26-000002 · form4-01022026_090107.xml · nonDerivative · entry 2 Winter Charles M. · CIK 0001960264 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,321 F3 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. Read SEC document |
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,401 | $13.73 | $32,965.73 |
DisclosureSEC source: 0001960264-26-000002 · form4-01022026_090107.xml · nonDerivative · entry 1 Winter Charles M. · CIK 0001960264 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,721 F1 · kind: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · balance_after: Includes 2,834 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 80,500 | $0.00 Strike: $53.24 | $0.00 |
DisclosureSEC source: 0001415889-25-000676 · form4-01032025_080109.xml · derivative · entry 2 Winter Charles M. · CIK 0001960264 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,500 Underlying: Common Stock · 80,500 shares Expires 2035-01-01 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000676 · form4-01032025_080109.xml · nonDerivative · entry 1 Winter Charles M. · CIK 0001960264 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,288 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. F2 · balance_after: Includes 1,297 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,644 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023, 2,834 shares acquired under the Plan on May 15, 2024 and 1 share acquired under the Plan on November 15, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:54 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 111,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-24-000440 · doc4.xml · derivative · entry 1 Winter Charles M. · CIK 0001960264 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock · 111,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:36 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-23-001886 · doc4.xml · derivative · entry 1 Winter Charles M. · CIK 0001960264 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.